Apoptosis is a critical early cellular event in the development of polycystic kidney disease (PKD) in humans and mice. In the SBM transgenic model of PKD, ... M Couillard,R Guillaume,N Tanji,... - 《Cancer Research》 被引量: 65发表: 2002年 加载更多来源...
The novel finding that rapamycin decreases hypertension, heart enlargement and mTOR signalling in the heart in PKD rats is reported. The only side effect of rapamycin treatment was an 11% decrease in body weight. 展开 关键词: chronic kidney disease heart mTOR polycystic kidney rapamycin ...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening inherited kidney disease and is responsible for 5–10% of cases of end-stage kidney disease (ESKD). Cystic kidneys may enlarge up to 20 times the weight of a normal kidney due to the growth of...
increased levels and activation of EGFR(HER-1) or HER-2(neu/ErbB2) have been reported in several human malignancies including those of the breast, pancreas, lung, head and neck, colon, prostate, stomach and ovaries, and the kidney and predicts an aggressive course of disease and poor progno...
MFF is the predominant DRP1 receptor in mammalian cells (Otera et al., 2010) and is highly expressed in tissues with high energy demands, such as heart, brain, muscle, kidney, and liver (Gandre-Babbe and van der Bliek, 2008). Knockdown of MFF results in elongated mitochondria, whereas ...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common cause of inherited kidney failure, affecting >1:1000 individuals worldwide [1,2]. ADPKD results from mutations in one of two genes, PKD1 and PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively ...
While there is one FDA-approved therapy, it is associated with potential adverse effects, and all other clinical interventions are largely supportive. Insights into the cellular pathways underlying ADPKD have revealed striking similarities to cancer. Moreover, several drugs originally developed for cancer...